Crossmark

[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Crossref DOI link: https://doi.org/10.1016/j.ad.2022.06.001

Published Print: 2022-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Serra-Baldrich, E.

Santamaria-Babí, L.F.

Francisco Silvestre, J.
License Information

Text and Data Mining valid from 2022-07-01

Version of Record valid from 2022-06-09
More Information

This article is maintained by: Elsevier

Article Title: [Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2022.06.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.ad.2021.12.014

Content Type: article

Copyright: © 2021 AEDV. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below